Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad26 COV2 S - Johnson & Johnson Innovative Medicine

Drug Profile

Ad26 COV2 S - Johnson & Johnson Innovative Medicine

Alternative Names: 'Wuhan coronavirus vaccine - Johnson & Johnson Innovative Medicine; 2019-nCoV vaccine - Johnson & Johnson Innovative Medicine; Ad26 COVS1; Ad26-S.PP; Ad26.COV2 S; Ad26.COV2-S recombinant - Johnson & Johnson Innovative Medicine; Ad26.COV2.S; Coronavirus vaccine - Johnson & Johnson Innovative Medicine; Janssen COVID-19 Vaccine; Jcoviden; JNJ-78436735; Johnson & Johnson COVID-19 vaccine; Single-dose COVID-19 vaccine - Johnson & Johnson Innovative Medicine; Single-Shot Janssen COVID-19 Vaccine; VAC 31518

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceuticals
  • Developer Janssen Vaccines and Prevention B.V; Johnson & Johnson Innovative Medicine
  • Class COVID-19 vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 24 Nov 2023 Janssen Vaccines & Prevention B.V.completes a phase II trial for COVID-2019 infection (Prevention) in South Africa, Spain, and USA (IM) (NCT04765384)
  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
  • 14 Aug 2023 Janssen Vaccines & Prevention completes a phase II trial in COVID-2019 infections (In adolescents, Prevention) in Brazil, Argentina, India, Mexico, South Africa (IM) (NCT05007080)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top